Why only 3 months? Immunological constraints on CAR-T therapy in gastrointestinal cancers
In June 2026, satri-cel/CT041, a chimeric antigen receptor (CAR) T-cell product targeting Claudin18.2, received approval from China’s National Medical Products Administration for the treatment of Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after failure of at least tw...
Li-Ping Zeng, Sheng Wei, Nan Chen et al.
· Frontiers in Immunology · 0 citations